Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 13/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5971975 | 0.79 | LPAR3 (0.52) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| Water SCHEMBL18148967 | 0.79 | LPAR3 (0.91) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL5250599 | 0.78 | LPAR3 (0.55) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL19602981 | 0.78 | LPAR3 (0.55) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL6709164 | 0.77 | LPAR3 (0.55) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| Phosphoric Acid Monodecyl Ester SCHEMBL27532872 | 0.77 | LPAR3 (0.95) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| Water SCHEMBL27325621 | 0.77 | LPAR3 (0.72) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| Water SCHEMBL26965726 | 0.77 | LPAR3 (0.95) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL56778 | 0.76 | LPAR3 (0.95) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL1582974 | 0.76 | LPAR3 (0.95) | LPAR3LPAR2LPAR1CYP3A4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | Asta Pharmaceuticals Co., Ltd. (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3147279-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | Fuji Chemical Industry Co., Ltd. (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | FUJI CHEMICAL INDUSTRIES CO., LTD. (JP) | 2017-03-23 | — | — | US | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | NR2E3, NR3C2, NR5A1 | LPAR3 954/4885LPAR2 3320/4885LPAR1 2660/4885 |
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | NR2E3, NR3C2, NR5A1 | LPAR3 954/4885LPAR2 3320/4885LPAR1 2660/4885 |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | LPAR3 3098/4885LPAR2 2846/4885LPAR1 2436/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | LPAR3 3098/4885LPAR2 2846/4885LPAR1 2436/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | LPAR3 4071/4885LPAR2 4306/4885LPAR1 4254/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | LPAR3 4111/4885LPAR2 4342/4885LPAR1 4298/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | LPAR3 979/4885LPAR2 1018/4885LPAR1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.